Nvidia’s investment isn’t just working capital for Recursion Pharmaceuticals’ technology-driven drug discovery research. Recursion says it will get more computing power as well as the possibility of joining forces with Nvidia in research.
Recursion Pharmaceuticals is acquiring two Canada-based artificial intelligence startups, Cyclica and Valence. The “biology-first company” says both deals build up its capability to apply AI to the chemistry side of drug discovery.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Amylyx Pharmaceuticals has submitted its amyotrophic lateral sclerosis (ALS) drug for FDA review based on positive Phase 2 data after discussions with the agency over the summer. Meanwhile, a Clene Nanomedicine ALS drug failed its Phase 2 study, but the biotech points to encouraging results in a subgroup of patients.
Intermountain Healthcare plans to close 25 of its retail pharmacies, and will transfer those prescriptions to CVS Pharmacy starting next month. The change will affect about 250 employees.
Health Catalyst will buy patient engagement startup Twistle for $104 million. The deal would combine Twistle’s capabilities to securely message patients with Health Catalyst’s repository of patient data.
The partnership includes a $30 million upfront payment from Bayer and potentially more than $100 million in milestones per program generated through the partnering of the German drugmaker's molecule library and Recursion's artificial intelligence-based drug discovery platform.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
PhotoPharmics has raised $11 million and aims to raise another $10 million to help in the development and commercialization of its specialized light therapy device to treat Parkinson's Disease.
The test, designed at Rutgers University under a partnership with Spectrum Solutions and Accurate Diagnostic Labs, is designed to allow for broader population screening than the current, more prevalent method of nose and throat swabs.
Rivet, a startup that helps providers keep track of insurance contracts and billing, closed an $8.25 million funding round. Technology venture capital company Menlo Ventures led the funding round.
Salt Lake City-based Myriad Genetics' GeneSight screening analyzes specific genes as a way to predict the effectiveness of 56 common medications for depression.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Both Livongo and Health Catalyst held their IPOs today and saw their stock price soar more than 40 percent in early trading.
Recursion's technology works by generating millions of cellular images and using AI-based software as a way to analyze the data set and screen potential therapeutic compounds against a variety of diseased cells.
The idea behind the new company - dubbed Castell - is to use Intermountain's resources and learnings from its own efforts to shift to value-based care to help other providers on that journey.
Vizient, a healthcare performance improvement company, will use its analytics and data capabilities to help Civica Rx anticipate gaps in drug availability and affordability.
The 30,000-square-foot facility in Salt Lake City will be used for evaluating, testing and designing new revenue cycle management technologies for hospitals, health systems and physician groups and will also serve as a client experience center.